Health Condition 1: C509- Malignant neoplasm of breast of unspecified site
Conditions
Interventions
Intervention1: Not applicable: Not applicable
Non interventional study
Control Intervention1: Not applicable: Not applicable
Sponsors
Department of Biotechnology
Department Of Science Technology
Eligibility
Inclusion criteria
Inclusion criteria: 1)Women of age 18-65 years who are radiologically or histopathologically diagnosed with breast cancer of any receptor expression / subtype 2) Who are eligible for upfront sugery and who consent for biobanking of their tumour and adjacent normal from primary tumour site at time of diagnostic biopsy or surgical ressection 3)Who have disease progression and/or disease relapse on any form of treatment requiring a diagnostic biopsy to determine further course of treatmentconsenting to biobanking of tumour and adjacent normal from site of disease progression/relapse and/or metastatic tumour site at time of their diagnostic biopsy 4) Who are denovo metastatic at presentation / diagnosis and consent for biobanking of tumour and adjacent normal from primary tumour site and/or metastatic tumour site at time of diagnostic biopsy
Exclusion criteria
Exclusion criteria: 1)Women who are socio-vulnerable (Unable to comprehend study, not deemed mentally fit to take a decision on their own) 2)Women who don’t consent for biopsy 3)Women whose tumour tissue does not have any tumour content and/or are not diagnosed with cancer on histopathological examination of biopsy specimen
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Here, we propose the development of patient-derived 3D tumor model using functional amyloid hydrogel as a scaffold for screening novel anticancer therapeutics and evaluating the efficacy of existing drugs.Timepoint: 36 months | — |
Secondary
| Measure | Time frame |
|---|---|
| NATimepoint: NA | — |
Countries
India
Contacts
Public ContactYogesh Kembhavi
Tata Memorial Center
Outcome results
None listed